ArticleCancer research2021
GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Deletion of 17p in cancers: Guilt by (p53) association.Oncogene · 2025Review
- Genome-Wide DNA Methylation Profiling as a Prognostic Marker in Pituitary Adenomas-A Pilot Study.Cancers · 2024Article
- The METTL3/miR-196a Axis Predicts Poor Prognosis in Non-small Cell Lung Cancer.Journal of Cancer · 2024Article
- Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer.Epigenetics · 2023Article
- Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Metastasis in neuroblastoma: theFrontiers in oncology · 2023Review
- SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.Journal of experimental & clinical cancer research : CR · 2022Article
- One Host-Multiple Applications: Zebrafish (International journal of molecular sciences · 2022Review
- Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.Translational cancer research · 2022Article
- Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma.Computational and structural biotechnology journal · 2022Article
- Identification of Tumor Suppressive Genes Regulated byInternational journal of molecular sciences · 2021Article
- Review
Corrections and comments
- Commented on by
Authors and funding
28 authors at 5 institutions in 3 countries.
Zhiwei Dong *Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.ORCID 0000-0001-8618-7918
Kok Siong Yeo *Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.ORCID 0000-0003-2430-2487
Gonzalo LopezDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-5092-1284
Cheng ZhangDepartment of Molecular Pharmacology & Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.
Erin N Dankert EggumDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Jo Lynne RokitaCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0003-2171-3627
Choong Yong UngDepartment of Molecular Pharmacology & Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.
Taylor M LeveeDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Zuag Paj HerDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Cassie J HoweDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Xiaonan HouDepartments of Oncology, Radiation Oncology, and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Janine H van ReeDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Shuai LiDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Shuning HeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ting TaoChildren's Hospital, Zhejiang University School of Medicine; National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China.ORCID 0000-0003-1260-2351
Karen FritchieDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Jorge Torres-MoraDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Julia S LehmanDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota.
Alexander MevesDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota.
Gina L RazidloDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.ORCID 0000-0002-9042-2738
Komal S RathiCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
S John WerohaDepartments of Oncology, Radiation Oncology, and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
A Thomas LookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7851-8617
Jan M van DeursenDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Hu LiDepartment of Molecular Pharmacology & Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.
Jennifer J WestendorfDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
John M MarisDepartment of Bioinformatics and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0002-8088-7929
Shizhen ZhuDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota. Zhu.shizhen@mayo.edu.ORCID 0000-0002-2929-3279
Mayo Clinic · USChildren's Hospital of Philadelphia · USDana-Farber Cancer Institute · USChildren's Hospital of Zhejiang University · CNIcahn School of Medicine at Mount Sinai · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MDiscovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7MMechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in CancerR35CA210064 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2016 to 2022
$7.3MThe Genetic Basis of Neuroblastoma TumorigenesisR01CA124709 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MARIS, JOHN M · 2008 to 2017
$6.3MRole of LMO1 in Neuroblastoma Initiation and MaintenanceR01CA180692 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI LOOK, A. THOMAS, MARIS, JOHN M · 2015 to 2019
$3.0MInterplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasisR01CA240323 · NCI · MAYO CLINIC ROCHESTER · PI ZHU, SHIZHEN · 2020 to 2024
$1.8MPrecision Medicine by Targeting Cell Adhesion in MelanomaK08CA215105 · NCI · MAYO CLINIC ROCHESTER · PI MEVES, ALEXANDER · 2017 to 2021
$854kNCI NIH HHS K08 CA215105NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA124709NCI NIH HHS R01 CA180692NCI NIH HHS R01 CA240323NCI NIH HHS R35 CA210064NCI NIH HHS R35 CA220500
Abstract
One of the greatest barriers to curative treatment of neuroblastoma is its frequent metastatic outgrowth prior to diagnosis, especially in cases driven by amplification of the
Indexed as
Chromosome DeletionGene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorBone Marrow NeoplasmsCell ProliferationHumansMiceMice, SCIDNerve Tissue ProteinsNeuroblastomaN-Myc Proto-Oncogene ProteinPrognosisSurvival RateTumor Cells, CulturedBiomarkers, TumorGAS7 protein, humanMYCN protein, humanNerve Tissue ProteinsN-Myc Proto-Oncogene Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.